This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/8/1752    most recent ATVBAHA.107.144352v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Deng, W.-G. Articles by Wu, K. K. Search for Related Content PubMed PubMed Citation Articles by Deng, W.-G. Articles by Wu, K. K.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1752.)
© 2007 American Heart Association, Inc.

Vascular Biology

Interferon- Suppresses Cyclooxygenase-2 Promoter Activity by Inhibiting C-Jun and C/EBPß Binding

Wu-Guo Deng; Alberto J. Montero; Kenneth K. Wu

From the University of Texas Health Science Center (W.-G.D., A.J.M., K.K.W.) and M.D. Anderson Cancer Center (W.-G.D., A.J.M., K.K.W.), Houston, Tex; and the National Health Research Institutes (K.K.W.), Zhunan, Miaoli, Taiwan. Present address for A.J.M.: Department of Internal Medicine, Medical University of South Carolina, Charleston.

Correspondence to Kenneth K. Wu, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan. E-mail kkgo{at}nhri.org.tw; or University of Texas Health Science Center, 6431 Fannin, MSB 5.016, Houston, TX 77030-1503. E-mail Kenneth.K.Wu@uth.tmc.edu

Objective— Cyclooxygenase-2 (COX-2) and interferon (IFN) are overexpressed in vascular inflammatory and atherosclerotic lesions. We postulated that IFN suppresses COX-2 expression at the transcriptional level.

Methods and Results— The effect of IFN on COX-2 expression was evaluated in several types of human cells stimulated with phorbol 12-myristate 13-acetate (PMA), interleukin (IL)-1ß, or tumor necrosis factor (TNF) . IFN concentration-dependently inhibited COX-2 proteins and promoter activities induced by PMA or cytokines in human fibroblasts and monocytic and endothelial cells. PMA and cytokines stimulate binding of C-Jun, C-Fos, CCAAT/enhancer binding protein ß (C/EBPß), or NF-B to their respective regulatory elements on COX-2 promoter. IFN blocked C-Jun and C/EBPß but not C-Fos or p50 NF-B binding as determined by in vitro binding assays and chromatin immunoprecipitation assay. p300 binding to COX-2 promoter was inhibited by IFN in a manner comparable to C-Jun and C/EBPß binding.

Conclusions— IFN suppresses proinflammatory mediator-induced COX-2 transcription by selective inhibition of C-Jun and C/EBPß DNA binding activity and p300 recruitment in human cells. Because IFN is coexpressed with COX-2 in vascular lesions, it may play a role in controlling COX-2–mediated inflammatory changes.

INF- suppressed proinflammatory mediator-induced transcriptional activation in human cells by selective inhibition of C-Jun and C/EBPß binding to their respective response elements on COX-2 promoter. We propose that IFN may represent an important factor for controlling COX-2–mediated vascular inflammatory diseases including the development of atheromatous plaque.

Key Words: interferon • cyclooxygenase-2 • atherosclerosis • plaque instability • inflammation